Retroscreen Virology signs agreement with pharmaceutical company
Retroscreen Virology Group, which creates drugs and vaccines for a number of viral respiratory diseases, has signed a Viral Challenge Model contract with a major global pharmaceutical company for the provision of a respiratory syncytial virus (RSV) challenge study.
Retroscreen Virology Group, which creates drugs and vaccines for a number of viral respiratory diseases, has signed a Viral Challenge Model contract with a major global pharmaceutical company for the provision of a respiratory syncytial virus (RSV) challenge study.
The contract, valued at £5.9m, will be the largest RSV challenge study conducted by Retroscreen to-date.
Kym Denny, Chief Executive Officer, said: "We are delighted to be working with such an innovative pharmaceutical company on the development of their novel product.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
"This contract win comes from the building momentum of Retroscreen's sales pipeline and highlights the pharmaceutical industry's increasing awareness of the benefits of the VCM in accelerating drug development and product decision-making."
NR
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
Shein shifts IPO focus to Hong Kong
The development piles fresh pressure on London’s beleaguered stock market, which many had hoped would be boosted by Shein’s IPO
-
Scientists turn lead into gold – could it wreck the yellow metal's price?
Medieval alchemists have been vindicated after scientists turned lead into gold, but the results aren’t going to crash the gold price any time soon